Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Neck”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 505 records · Page 28Linked to original sources
PubMed1990

The cat cervical dorsal root ganglia: general cell-size characteristics and comparative study of neck muscle, neck cutaneous and phrenic afferents.

Sizes of neuronal somata in the cat cervical dorsal root ganglia were determined at different levels (C1-C8). The average value and class distribution of mean cell diameter were analyzed. The ganglia from C1 to C5 could be clearly distinguished from those at levels of brachial plexus afferents (C6-C8) with respect to cell size range, distribution and average. The size distribution, most often limited to 70 microns from C1 to C5, skewed to more than 90 microns from C6 to C8. Cells in the 35-50 microns range of diameter constituted the main portion of the cell population (49-52%) at the C1-C5 levels, whereas from C6 to C8 51-77% of the ganglion cell bodies were more than 50 microns in diameter. The cell size distribution of afferents projecting from C1 to C5 and supplying different muscle or cutaneous targets was studied following retrograde labeling with horseradish peroxidase conjugated to wheatgerm agglutinin. Sizes of cell bodies of biventer cervicis (postural muscle), phrenic (purely respiratory muscle) and cutaneous afferents were all similar. The labelled cell bodies were in the majority (51-64%) less than 35 microns in diameter and ranged towards smaller diameters than counterstained cells in the corresponding ganglia. In spite of similarities in cell size distribution it was estimated from the fiber caliber spectra of the labelled afferents that both unmyelinated and myelinated cutaneous afferents originate from larger cell bodies than muscle afferents in the same diameter range.

Adolescent↗
PubMed1996

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.

BACKGROUND: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma. PATIENTS AND METHODS: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks. RESULTS: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease. CONCLUSION: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.

Adult↗